Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioInvent International AB: BioStock: BioInvent's BI-1808 gains broad FDA support

BioInvent International

BioInvent has secured a win with the FDA granting Orphan Drug Designation to BI-1808 for T-cell lymphoma (TCL), a broad category covering multiple subtypes, including cutaneous T-cell lymphoma (CTCL). This news, paired with previously disclosed promising early data, arrives as the company anticipates further BI-1808 data by mid-2025, with additional readouts expected from its portfolio of six ongoing clinical programs throughout the year.

Read the article at biostock.se:

https://www.biostock.se/en/2025/03/bioinvents-bi-1808-gains-broad-fda-support/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.